PB 36 of 2025
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2025
I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 26 March 2025
Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments commencing 1 April 2025
National Health (Minimum Stockholding) Determination 2023
Schedule 2—Amendments commencing 1 October 2025
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 3) 2025.
(2) This instrument may also be cited as PB 36 of 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 April 2025. | 1 April 2025 |
2. Schedule 1 | 1 April 2025. | 1 April 2025 |
3. Schedule 2 | 1 October 2025. | 1 October 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1 (table)
Omit:
Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
2 Schedule 1 (table)
Omit:
Aripiprazole | Tablet 15 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |
3 Schedule 1 (table)
Omit:
Aripiprazole | Tablet 20 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |
4 Schedule 1 (table)
Omit:
Aripiprazole | Tablet 30 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |
5 Schedule 1 (table)
Omit:
Bisacodyl | Tablet 5 mg | Oral | Lax-Tab | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
6 Schedule 1 (table)
After:
Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together |
insert:
Cefotaxime | Powder for injection 1 g (as sodium) | Injection | DBL Cefotaxime | between 1 April 2025 and 30 April 2025—0 months stock by reference to usual demand |
7 Schedule 1 (table)
Omit:
Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)-100 mg | Oral | Clopidogrel Winthrop plus aspirin | between 1 December 2024 and 31 March 2025—0 months stock by reference to usual demand |
8 Schedule 1 (table)
After:
Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | Zeklen 10/10 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |
9 Schedule 1 (table)
After:
Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | Zeklen 10/20 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |
10 Schedule 1 (table)
After:
Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | Zeklen 10/40 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |
11 Schedule 1 (table)
After:
Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Zeklen 10/80 mg | between 1 April 2025 and 30 June 2025—0 months stock by reference to usual demand |
12 Schedule 1 (table)
After:
Furosemide | Oral solution 10 mg per ml, 30 ml | Oral | Lasix | (a) between 1 November 2024 and 31 March 2025—4 months stock by reference to usual PBS demand (b) after 31 March 2025—6 months stock by reference to usual PBS demand |
insert:
Furosemide | Tablet 40 mg | Oral | NOUMED FUROSEMIDE | between 1 April 2025 and 31 May 2025—0 months stock by reference to usual demand |
13 Schedule 1 (table)
Omit:
Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral | Presolol 100 | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
14 Schedule 1 (table)
Omit:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Chemists' Own Macrogol with Electrolytes | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
15 Schedule 1 (table)
After:
Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox (Combination Pack) | 6 months stock by reference to usual PBS demand |
insert:
Methylprednisolone | Powder for injection 40 mg (as sodium succinate) with diluent | Injection | Solu-Medrol | between 1 April 2025 and 30 April 2025—0 months stock by reference to usual demand |
16 Schedule 1 (table)
After:
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | APX-Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together |
insert:
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Viatris | after 31 July 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together |
17 Schedule 1 (table)
After:
Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Mycophenolate APOTEX | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together |
insert:
Naloxone | Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe | Injection | Prenoxad | between 1 April 2025 and 30 September 2025—4 months stock by reference to usual demand |
18 Schedule 1 (table)
Omit:
Piroxicam | Dispersible tablet 20 mg | Oral | Feldene-D | between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand |
19 Schedule 1 (table)
After:
Ramipril | Capsule 10 mg | Oral | Prilace | 5.5 months stock by reference to usual demand |
insert:
Ramipril | Capsule 10 mg | Oral | Ramipril Winthrop | between 1 April 2025 and 31 May 2025—0 months stock by reference to usual demand |
20 Schedule 1 (table)
After:
Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | 5 months stock by reference to usual demand |
insert:
Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Ventolin CFC-Free with dose counter | 4 months stock by reference to usual demand |
21 Schedule 1 (table)
After:
Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
insert:
Tamoxifen | Tablet 20 mg (as citrate) | Oral | Tamosin | between 1 April 2025 and 30 September 2025—0 months stock by reference to usual demand |
22 Schedule 1 (table)
Omit:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 January 2025 and 31 March 2025—2 months stock by reference to usual demand |
23 Schedule 1 (table)
Omit:
Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Kanjinti | between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand |
1 Schedule 1 (table)
After:
Levetiracetam | Tablet 1 g | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
insert:
Levetiracetam | Tablet 1 g | Oral | LEVETIRACETAM-WGR | 6 months stock by reference to usual demand |